Loading...
Loading...
ALVOW| Name | Value |
|---|---|
| Revenues | 102.9M |
| Cost of Revenue | 39.8M |
| Gross Profit | 63.1M |
| Operating Expense | 50.3M |
| Operating I/L | 12.7M |
| Other Income/Expense | -37.5M |
| Interest Income | 77.4M |
| Pretax | -24.8M |
| Income Tax Expense | -13.4M |
| Net Income/Loss | -11.4M |
Alvotech Holdings SA and its subsidiaries specialize in the development and manufacturing of biosimilars for global markets. By creating high-quality and cost-effective alternatives to existing biologic drugs, the company aims to address the growing demand for affordable biopharmaceuticals. With a focus on biosimilar products, Alvotech generates revenue through the sale and distribution of these pharmaceuticals to healthcare providers, pharmacies, and other stakeholders in the global market.
